You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
NORTHBROOK, Ill., June 6, 2017 /PRNewswire/ -- Astellas today announced data from an exploratory analysis of the Phase I/II CHRYSALIS study, which demonstrated that FLT3 mutation-positive...
-Pivotal Monotherapy Phase 2 Trial Initiation Planned for 2017- CHICAGO, June 5, 2017 /PRNewswire/ -- Astellas and Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted updated phase 1 data for...
NORTHBROOK, Ill., May 25, 2017 /PRNewswire/ -- Today, Great Place to Work® and Fortune magazine announced their inaugural 50 Best Workplaces in Chicago list. Astellas ranked among the Top 20 best...
NORTHBROOK, Ill., May 19, 2017 /PRNewswire/ -- Today, Astellas was named an honoree of the 2017 When Work Works award by the Society for Human Resource Management (SHRM). The award honors...
NORTHBROOK, Ill., May 17, 2017 /PRNewswire/ -- Astellas announced today that a wide selection of abstracts highlighting the Company's diverse oncology portfolio across a broad range of cancers...
Follow U.S. news
